Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.Frontiers in public health · 2026
   Article
2. Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025.Frontiers in public health · 2026
   Article
3. High Effectiveness of the Changchun Baike Varicella Vaccine in a Real-World Outbreak Setting: An Observational Study from Yanji City, China.Vaccines · 2025
   Article
4. Surveillance of psychogenic adverse events following immunization in Zhejiang, China, 2020-2023.BMC public health · 2025
   Article
5. Adverse Events FollowingVaccines · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as